Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880063 | 0.98 | CTSK (0.46) | CTSKHPGDCA1CA2SMN1; SMN2 | |
| SCHEMBL945981 | 0.96 | MAPT (0.43) | CTSKHPGDCA1CA2SMN1; SMN2 | |
| SCHEMBL4738498 | 0.84 | EPHX2 (0.38) | CTSKHPGDCA1CA2SMN1; SMN2 | |
| SCHEMBL7040760 | 0.76 | CTSK (0.38) | CTSKHPGDCA1CA2SMN1; SMN2 | |
| SCHEMBL7040763 | 0.76 | CTSK (0.38) | CTSKHPGDCA1CA2SMN1; SMN2 | |
| SCHEMBL8191259 | 0.75 | HPGD (0.39) | CTSKHPGDCA1CA2GAA | |
| SCHEMBL8191256 | 0.75 | HPGD (0.39) | CTSKHPGDCA1CA2GAA | |
| SCHEMBL2025016 | 0.74 | HPGD (0.47) | CTSKHPGDCA1CA2SMN1; SMN2 | |
| SCHEMBL9106442 | 0.74 | HPGD (0.41) | CTSKHPGDCA1CA2SMN1; SMN2 | |
| Ethyne SCHEMBL9752605 | 0.74 | HPGD (0.64) | CTSKHPGDSMN1; SMN2MAPTPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606038-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | claimed |
| US-8765944-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | claimed |
| EP-2606038-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-06-26 | — | — | EP | claimed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | claimed |
| WO-2012024373-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | WO | claimed |
| WO-2024137742-A1 | COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-2606038-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8765944-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2606038-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2012024373-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-1380582-B1 | FSH mimetics for the treatment of infertility | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| EP-1102763-B1 | FSH MIMETICS FOR THE TREATMENT OF INFERTILITY | APPLIED RESEARCH SYSTEMS (AN) | 2004-10-13 | — | — | EP | disclosed |
| EP-1380582-A1 | FSH mimetics for the treatment of infertility | Applied Research Systems ARS Holding N.V. (AN) | 2004-01-14 | — | — | EP | disclosed |
| US-6653338-B2 | Heterocyclic carboxamide compounds | APPLIED RESEARCH SYSTEMS ARS HOLDING N.A. (NL) | 2003-11-25 | — | — | US | disclosed |
| US-20020147345-A1 | FSH mimetics for the treatment of infertility | MERCK SERONO SA (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6423723-B1 | ORAL BIOAVAILABILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N. A. (NL) | 2002-07-23 | — | — | US | disclosed |
| EP-1102763-A2 | FSH MIMETICS FOR THE TREATMENT OF INFERTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2001-05-30 | — | — | EP | disclosed |
| US-6235755-B1 | FOLLICLE STIMULATING HORMONE ANTAGONIST | APPLIED RESEARCH SYSTEMS ARS HOLDING N.A. (AN) | 2001-05-22 | — | — | US | disclosed |
| WO-2000008015-A2 | FSH MIMETICS FOR THE TREATMENT OF INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147345-A1 | FSH mimetics for the treatment of infertility | FSHR, GNRHR, LHCGR | CTSK 2023/4885HPGD 3083/4885CA1 3182/4885 |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | CTSK 520/4885HPGD 1433/4885CA1 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.